Hadean Capital II will be investing in line with the strategy of Hadean Capital I, including in start-up companies within pharma, biotech, medtech diagnostics and digital health. The geographic focus will mainly be on European companies, with a particular attention to areas considered “under-ventured” such as the Nordics and certain regions of DACH.
Hadean Capital II is supported by over 30 private and institutional investors including OPF, Saminvest, Argentum and Investinor.
Ingrid Teigland Akay, MD MBA, Managing Partner, commented: “It is a pleasure to welcome new and returning investors to Hadean Capital II. We are excited to continue to support start-up founders who build companies to bring break-through medical innovation to the market.”
Walter Stockinger, PhD, Managing Partner, added: “We are pleased to see that the strategy we set out for our first fund is delivering and we are confident that our growing team of highly skilled and diverse investment professionals will be able to leverage the untapped potential we see in the European life science ecosystem.”
About Hadean Ventures
Hadean Ventures is a life science fund manager that invests in life science companies across Europe. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in Oslo and Stockholm and collaborates with world-class academic institutions and start-up hubs across the region.
Ingrid Teigland Akay, Managing Partner
Ingrid Beyer, Head of IR and Business Development
+47 905 94882
This information was brought to you by Cision http://news.cision.com